Working… Menu

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer (PanCAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02967770
Recruitment Status : Withdrawn (Issues with patient recruitment.)
First Posted : November 18, 2016
Last Update Posted : September 11, 2018
Thomas Jefferson University
Sinai Health System
Virginia Mason Hospital/Medical Center
Cedars-Sinai Medical Center
George Mason University
Caris Life Sciences, Inc
Theranostics Health, Inc
Guardant Health, Inc.
Companion Diagnostics, Inc.
Information provided by (Responsible Party):
Georgetown University

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : August 30, 2018
Actual Study Completion Date : August 30, 2018